This press release is available in German.
Conventional blood pressure medication can treat inflammation in an animal model mimicking multiple sclerosis (MS). This discovery was made by Dr. Michael Platten, head consultant at the department of Neurooncology at Heidelberg University Hospital and head of the Helmholtz Experimental Neuroimmunology Junior Research Group on at the German Cancer Research Center and his team in cooperation with scientists from Stanford University in California. Blood pressure medication called ACE inhibitors and AT1R blockers can suppress inflammation in mice suffering from an autoimmune disease comparable to MS. The results are published in the Proceedings of the National Academy of Sciences (PNAS) back-to-back with a report of a Bochum team that also supports the new role for ACE inhibitors.
The renin-angiotensin-aldosterone system (RAAS) is a system of messengers and receptors that regulates blood pressure. The angiotensin-converting enzyme (ACE) produces angiotensin II, which increases blood pressure. This effect is mediated mainly via the angiotensin 1 receptor (AT1R). Medications that inhibit the ACE enzyme or block the AT1R receptor are used by millions to lower blood pressure. Scientific trials and clinical observations have increased the suspicion that RAAS also plays a decisive role in immunological processes.
Inflammation and paralysis reversed
In their tests, the Heidelberg researchers first showed that the RAAS was actually elevated in MS foci in the brains of deceased MS patients. They then treated mice that had an autoimmune disease of the nervous system similar to MS with ACE inhibitors and AT1R blockers. The results were astonishing - the drugs suppressed specific immune cells that were instrumental in promoting inflammation. In addition, they increased anti-inflammatory immune cells that reversed existing neuroinflammation and subsequent paralysis.
Clinical studies to follow soon
Since the animal model the researches employed is an established model that is frequently used for drug development in MS, the researchers hope that the results are transferable to humans. Clinical trials analyzing the efficacy of ACE inhibitors in MS patients are currently being planned. "The use of this blood pressure medication is an attractive strategy for treating autoimmune diseases. The drugs are already used by millions of people, are cheap, and have few side effects," explains Professor Lawrence Steinman, partner of the Heidelberg researchers at Stanford University.
Blocking angiotensin converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Michael Platten, Sawsan Youssef, Eun-Mi Hur, Peggy P Ho, May H. Han, Tobias Lanz, Lori K. Phillips, Matthew J Goldstein, Roopa Bhat, Cedric S. Raine, Raymond A Sobel, Lawrence Steinman, PNAS.
More Information in the Internet about the Department of Neurooncology: www.klinikum.uni-heidelberg.de/index.php?id=105540&L=en
Heidelberg University Hospital and Medical Faculty:
Internationally recognized patient care, research, and teaching
Heidelberg University Hospital is one of the largest and most prestigious medical centers in Germany. The Medical Faculty of Heidelberg University belongs to the internationally most renowned biomedical research institutions in Europe. Both institutions have the common goal of developing new therapies and implementing them rapidly for patients. With about 7,000 employees, training and qualification is an important issue. Every year, around 500,000 patients are treated on an inpatient or outpatient basis in more than 40 clinics and departments with 1,600 beds. Currently, about 3,100 future physicians are studying in Heidelberg; the reform Heidelberg Curriculum Medicinale (HeiCuMed) is one of the top medical training programs in Germany.
Requests by journalists:
Dr. Annette Tuffs
Head of Public Relations and Press Department
University Hospital of Heidelberg and
Medical Faculty of Heidelberg
Im Neuenheimer Feld 672
phone: +49 6221 / 56 45 36
fax: +49 6221 / 56 45 44
Selected english press releases online: